Center for Drug Evaluation and Research: Artificial Intelligence in Drug Manufacturing
Description:
This report discusses FDA's consideration of the application of its risk-based regulatory framework to the use of AI technologies in drug manufacturing. The authors of the report ask the public to provide feedback after reading this report.
Date:
February 28, 2023
Creator:
United States. Food and Drug Administration.
Partner:
UNT Libraries Government Documents Department